Experts recommend mAb protection against RSV as standard care for all infants

Human_Respiratory_Syncytial_Virus_(RSV)_-_52870479521

Source: NIAID

While RSV poses a serious threat to the health of infants and young children, prophylactic mAbs offer safe and effective protection for an entire season, according to international health organizations.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE